Arrowhead Pharmaceuticals (BSP:A2RR34) Cyclically Adjusted PS Ratio: (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:A2RR34 Arrowhead Pharmaceuticals Inc BSP:A2RR34
22 GF Score
Price R$55.48
GF Value R$32.07
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Arrowhead Pharmaceuticals  (BSP:A2RR34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.89 42.44 25.83 0.00 18.36

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.84 9.52 18.36 31.89 28.77

BSP:A2RR34 vs AXSM, MDGL, BMRN: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BSP:A2RR34
22GF Score
Arrowhead Pharmaceuticals Inc BSP:A2RR34
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Arrowhead Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Arrowhead Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.708/330.2130*330.2130
=2.708

Current CPI (Mar. 2026) = 330.2130.

Arrowhead Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.002 241.018 0.003
201609 0.002 241.428 0.003
201612 0.205 241.432 0.280
201703 0.377 243.801 0.511
201706 0.412 244.955 0.555
201709 0.365 246.819 0.488
201712 0.155 246.524 0.208
201803 0.025 249.554 0.033
201806 0.031 251.989 0.041
201809 0.525 252.439 0.687
201812 1.408 251.233 1.851
201903 1.885 254.202 2.449
201906 1.665 256.143 2.146
201909 1.766 256.759 2.271
201912 1.245 256.974 1.600
202003 1.131 258.115 1.447
202006 1.395 257.797 1.787
202009 0.403 260.280 0.511
202012 1.067 260.474 1.353
202103 1.780 264.877 2.219
202106 2.217 271.696 2.694
202109 1.938 274.310 2.333
202112 1.484 278.802 1.758
202203 6.999 287.504 8.039
202206 1.547 296.311 1.724
202209 1.564 296.808 1.740
202212 3.094 296.797 3.442
202303 7.045 301.836 7.707
202306 0.718 305.109 0.777
202309 0.742 307.789 0.796
202312 0.162 306.746 0.174
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.122 315.605 0.128
202503 23.237 319.799 23.994
202506 1.108 322.561 1.134
202509 9.976 324.800 10.142
202512 10.238 324.054 10.433
202603 2.708 330.213 2.708

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Arrowhead Pharmaceuticals (BSP:A2RR34) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of R$55.48 is trading 73% above its estimated GF Value™ of R$32.07. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BSP:A2RR34:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: R$32.07 vs. price of R$55.48 (73% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the BSP:A2RR34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Other Exchanges ARWR:USA0HI3:UKHDP1:Germany
Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
22GF Score

Get the complete analysis for BSP:A2RR34

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$55.48
Price
R$32.07
GF Value